TNFRSF13B
Basic information
Region (hg38): 17:16929816-16972118
Links
Phenotypes
GenCC
Source:
- immunodeficiency, common variable, 2 (Strong), mode of inheritance: AR
- immunodeficiency, common variable, 2 (Strong), mode of inheritance: AR
- common variable immunodeficiency (Supportive), mode of inheritance: AD
- immunodeficiency, common variable, 2 (Strong), mode of inheritance: AR
- immunodeficiency, common variable, 2 (Limited), mode of inheritance: AD
- immunodeficiency, common variable, 2 (Definitive), mode of inheritance: AR
- immunodeficiency, common variable, 2 (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Immunoglobulin A deficiency 2; Common variable immunodeficiency 2 | AD/AR | Allergy/Immunology/Infectious | In CVID2, prophylaxis and early and aggressive treatment of infections may be beneficial; In most cases, IGA deficiency 2 is not associated with any illness, though some may have increased infections and autoimmune disorders (other sequelae have been reported, but the molecular causes in these patients are unclear) | Allergy/Immunology/Infectious | 11720003; 16007086; 16049503; 16007087; 18981294; 19629655; 20156508; 22076597; 22627058 |
ClinVar
This is a list of variants' phenotypes submitted to
- Immunodeficiency,_common_variable,_2 (309 variants)
- not_provided (66 variants)
- Inborn_genetic_diseases (34 variants)
- not_specified (23 variants)
- TNFRSF13B-related_disorder (22 variants)
- Immunoglobulin_A_deficiency_2 (19 variants)
- Common_Variable_Immune_Deficiency,_Dominant (12 variants)
- Common_variable_immunodeficiency (4 variants)
- Immunodeficiency,_common_variable,_1 (4 variants)
- Immune_deficiency,_familial_variable (1 variants)
- IgAD1 (1 variants)
- Immunodeficiency,_common_variable,_10 (1 variants)
- See_cases (1 variants)
- Severe_SARS-CoV-2_infection,_susceptibility_to (1 variants)
- Hyper-IgM_syndrome_type_2 (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the TNFRSF13B gene is commonly pathogenic or not. These statistics are base on transcript: NM_000012452.3. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 67 | 74 | ||||
| missense | 160 | 15 | 182 | |||
| nonsense | 15 | |||||
| start loss | 1 | 1 | ||||
| frameshift | 10 | 23 | ||||
| splice donor/acceptor (+/-2bp) | 8 | |||||
| Total | 25 | 15 | 178 | 82 | 3 |
Highest pathogenic variant AF is 0.005440998
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| TNFRSF13B | protein_coding | protein_coding | ENST00000261652 | 5 | 42584 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 2.09e-15 | 0.000589 | 125547 | 0 | 201 | 125748 | 0.000800 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | -1.20 | 215 | 171 | 1.26 | 0.0000103 | 1895 |
| Missense in Polyphen | 69 | 41.182 | 1.6755 | 566 | ||
| Synonymous | -0.988 | 82 | 71.4 | 1.15 | 0.00000443 | 589 |
| Loss of Function | -2.17 | 18 | 10.4 | 1.73 | 5.35e-7 | 123 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.000879 | 0.000879 |
| Ashkenazi Jewish | 0.00507 | 0.00507 |
| East Asian | 0.00109 | 0.00109 |
| Finnish | 0.000139 | 0.000139 |
| European (Non-Finnish) | 0.000768 | 0.000756 |
| Middle Eastern | 0.00109 | 0.00109 |
| South Asian | 0.000294 | 0.000294 |
| Other | 0.000815 | 0.000815 |
dbNSFP
Source:
- Function
- FUNCTION: Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T- cell function and the regulation of humoral immunity. {ECO:0000269|PubMed:10956646, ECO:0000269|PubMed:10973284}.;
- Disease
- DISEASE: Immunoglobulin A deficiency 2 (IGAD2) [MIM:609529]: Selective deficiency of immunoglobulin A (IGAD) is the most common form of primary immunodeficiency, with an incidence of approximately 1 in 600 individuals in the western world. Individuals with symptomatic IGAD often have deficiency of IgG subclasses or decreased antibody response to carbohydrate antigens such as pneumococcal polysaccharide vaccine. Individuals with IGAD also suffer from recurrent sinopulmonary and gastrointestinal infections and have an increased incidence of autoimmune disorders and of lymphoid and non-lymphoid malignancies. In vitro studies have suggested that some individuals with IGAD have impaired isotype class switching to IgA and others may have a post-switch defect. IGAD and CVID have been known to coexist in families. Some individuals initially present with IGAD1 and then develop CVID. These observations suggest that some cases of IGAD and CVID may have a common etiology. {ECO:0000269|PubMed:16007086}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Primary immunodeficiency - Homo sapiens (human);Cytokine-cytokine receptor interaction - Homo sapiens (human);Intestinal immune network for IgA production - Homo sapiens (human);yaci and bcma stimulation of b cell immune responses;TNFR2 non-canonical NF-kB pathway;Cytokine Signaling in Immune system;Immune System;TNFs bind their physiological receptors;Syndecan-4-mediated signaling events;Syndecan-2-mediated signaling events
(Consensus)
Recessive Scores
- pRec
- 0.245
Intolerance Scores
- loftool
- 0.218
- rvis_EVS
- 0.53
- rvis_percentile_EVS
- 80.96
Haploinsufficiency Scores
- pHI
- 0.0639
- hipred
- N
- hipred_score
- 0.180
- ghis
- 0.569
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.953
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Tnfrsf13b
- Phenotype
- homeostasis/metabolism phenotype; renal/urinary system phenotype; immune system phenotype; neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; liver/biliary system phenotype;
Gene ontology
- Biological process
- B cell homeostasis;hematopoietic progenitor cell differentiation;adaptive immune response;cell surface receptor signaling pathway;negative regulation of B cell proliferation;tumor necrosis factor-mediated signaling pathway
- Cellular component
- plasma membrane;integral component of plasma membrane
- Molecular function
- protein binding;signaling receptor activity